Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials

@article{Maarouf2018TargetedTF,
  title={Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials},
  author={Melody Maarouf and Ashley K Clark and Dylan E. Lee and Vivian Yan Shi},
  journal={Journal of Dermatological Treatment},
  year={2018},
  volume={29},
  pages={441 - 449}
}
Abstract Purpose: Targeted, immune-modulating drugs are at the forefront of therapy for HS, and a comprehensive clinical trial registry is needed to facilitate data pooling and clinical efficacy comparison. Materials and methods: A systematic review of the ClinicalTrials.gov database was searched for planned, in-progress, completed, or terminated trials investigating the effect of targeted biologic therapies for hidradenitis suppurativa (HS). When results of RCTs were not available, case… Expand
Efficacy and safety of adalimumab in hidradenitis suppurativa
TLDR
Adalimumab administered weekly resulted in not only better clinical responses than placebo but also significantly improved disease severity and quality of life of patients with moderate-to-severe HS. Expand
Unconventional therapies for hidradenitis suppurativa
TLDR
Novel therapeutic options seem to be promising, but dermatologists will have to evaluate their effectiveness and safety in daily clinical practice, as many therapeutic options for HS will be available in the next years. Expand
Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms
TLDR
The pharmacological mechanisms implicated in topical therapies, antibiotic, hormonal, systemic immunomodulatory and biologic therapies for HS are discussed and it is plausible that small molecule targets (Janus kinase1 and phosphodiesterase 4) may provide effective new strategies for treatment of HS. Expand
Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?
TLDR
The role of therapeutic drug monitoring and other dose optimization strategies in improving clinical response in patients with hidradenitis suppurativa treated with tumor necrosis factor-α inhibitors is presented. Expand
Long‐term therapy with anakinra in hidradenitis suppurativa in three patients
Long-term therapy with anakinra in hidradenitis suppurativa in three patients Dear Editor, Anakinra is a recombinant interleukin-1 (IL-1) receptor antagonist (IL-1Ra) commonly used in rheumatologyExpand
Secukinumab and hidradenitis suppurativa: Friends or foes?
TLDR
A case of secukinumab-induced HS in a psoriasis patient successfully treated with adalimumab, and a case of HS and related psoriasiform eruption caused by adalicumab treatment, controlled by secuk inumab therapy are described. Expand
Biologic Treatment for Hidradenitis Suppurativa
TLDR
Limitations in the use of biologics for HS include the many scoring systems utilized in research studies and the relatively few well-designed, adequately powered clinical trials. Expand
Part 2. Current and emerging treatments for hidradenitis suppurativa.
TLDR
The potential therapeutic roles of anti-cytokine therapies, including both the expanded application of existing molecules as well as the specific development of novel therapies for HS are discussed. Expand
Hidradenitis suppurativa: Current and emerging treatments.
TLDR
The potential therapeutic roles of anticytokine therapies, including both the expanded application of existing molecules as well as the specific development of novel therapies for HS are discussed. Expand
Updated Treatment for Acne: Targeted Therapy Based on Pathogenesis
TLDR
Future treatment for acne should embrace approaches that target the main etiological factors of acne, and specific emphasis on aggressive treatment in the acute inflammatory phase to reduce the likelihood of scarring and other clinical sequelae, such as pigmentary changes would be highly desirable. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 112 REFERENCES
A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa.
TLDR
Etanercept was generally well tolerated; however, two patients discontinued the study as a result of skin infections at the site of hidradenitis lesions requiring oral antibiotics. Expand
Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial.
TLDR
Anakinra has the potential to be an effective and well-tolerated treatment for HS and inhibition of interleukin 1 is a promising treatment strategy. Expand
Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report
TLDR
After 12 weeks of treatment with secukinumab, the number of lesions reported by the patient within the period of the last 4 weeks was reduced from 23 to seven, his pain visual analogue scale (VAS) score was reduced and pain/utility/handicap VAS score was reducing from 7 to 4, suggesting that IL‐17 blockade could provide a possible therapeutic approach in the treatment of HS. Expand
Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial.
TLDR
IFX was well tolerated, no unexpected safety issues were identified, and improvements in pain intensity, disease severity, and quality of life were demonstrated with concomitant reduction in clinical markers of inflammation. Expand
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
TLDR
Treatment with adalimumab (40 mg weekly), as compared with placebo, resulted in significantly higher clinical response rates in both trials at 12 weeks; rates of serious adverse events were similar in the study groups. Expand
An Update on Medical Treatment Options for Hidradenitis Suppurativa
TLDR
An overview of most drug treatments reported on for HS is provided, where possible with their mode of action and side effects, and surgical interventions are often needed to achieve remission. Expand
Hidradenitis suppurativa: the role of deficient cutaneous innate immunity.
TLDR
This study demonstrates for the first time, to the authors' knowledge, that a deficiency of the main innate immunity markers in typical HS sites may explain the development of chronic inflammatory nodules in this disease. Expand
Hidradenitis suppurativa: epidemiology, clinical features, associated comorbidities and treatment.
  • G. Shalom
  • Medicine
  • Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia
  • 2017
TLDR
No definitive treatment has been recognized, but several therapies have been found to reduce lesion severity and improve symptoms of HS, and additional research is needed for evaluation of the comparative effectiveness of topical and systemic treatments. Expand
Treatment of hidradenitis suppurativa with etanercept injection.
TLDR
Etanercept, 50 mg, SC administered twice weekly did not have significant efficacy in the improvement of HS, and it is suggested that future studies focus on other agents for the treatment of HS. Expand
Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment
TLDR
This review focuses on the main features of HS, including epidemiology, clinical aspects, pathogenesis, severity classifications, comorbidities, and currently available treatments. Expand
...
1
2
3
4
5
...